Validation of assay of catechol- O-methyltransferase activity in human erythrocytes
The multistep assay of specific catechol- O-methyltransferase (COMT) activity in human erythrocytes was validated. Enzyme preparations from lysed erythrocytes were incubated with a substrate (3,4-dihydroxybenzoic acid) in the presence of Mg 2+ and S-adenosylmethionine. The reaction products (vanilli...
Saved in:
Published in | Journal of pharmaceutical and biomedical analysis Vol. 14; no. 5; pp. 515 - 523 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
Amsterdam
Elsevier B.V
01.03.1996
Elsevier Science |
Subjects | |
Online Access | Get full text |
ISSN | 0731-7085 1873-264X |
DOI | 10.1016/0731-7085(95)01645-7 |
Cover
Summary: | The multistep assay of specific catechol-
O-methyltransferase (COMT) activity in human erythrocytes was validated. Enzyme preparations from lysed erythrocytes were incubated with a substrate (3,4-dihydroxybenzoic acid) in the presence of Mg
2+ and
S-adenosylmethionine. The reaction products (vanillic acid and isovanillic acid) were analyzable by HPLC with electrochemical detection directly in the incubation medium after protein precipitation. The precision was calculated in order to define the random variability associated with the method by intra-assay and inter-assay relative standard deviations (RSDs) for the assays of both reaction products and protein. The intra-assay RDSs for the specific activities were between 4.8 and 11.9% (
n = 5−6) at two levels of COMT activity. The inter-assay RSDs were between 6.4 and 14.2% (
n = 5−6), respectively. The total variation was mostly caused by the protein assay and the HPLC assay, and contributions from the sample preparation and incubation steps were minor.
Some results from the clinical application of the erythrocyte COMT assay are also reported. For both normal volunteers and patients having Parkinson's disease, a single 400 mg dose of entacapone, a peripherally acting COMT inhibitor, decreased the erythrocyte COMT activity. The application demonstrates that the assay was able to detect differences between the subjects and the effect of COMT inhibition in the clinical study. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0731-7085 1873-264X |
DOI: | 10.1016/0731-7085(95)01645-7 |